Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
2.
Int J Lab Hematol ; 44(2): 371-378, 2022 Apr.
Article in English | MEDLINE | ID: mdl-34643035

ABSTRACT

BACKGROUND: Heparin diminishes thrombin generation (TG) because it decreases the survival time of thrombin in plasma. Under heparin therapy, the TG curve therefore does not reflect the true hemostatic status of the patient. AIM: We investigated how far the in vitro addition of a heparin antagonist can restore the underlying TG capacity. MATERIALS & METHODS: Five different heparin antagonists were tested: polybrene, protamine sulfate, heparinase type 1, heparinase HEP-TEM, and (Z-GGR)2 -rhodamine (P2Rho). RESULTS AND CONCLUSION: Polybrene, P2Rho, and heparinase HEP-TEM effectively neutralized heparin at prophylactic and therapeutical doses of both low molecular weight and unfractionated heparin. The advantages and limits of each molecule and the most favorable combinations of TG-trigger and antagonist are discussed.


Subject(s)
Thrombin , Thrombophilia , Anticoagulants , Heparin/adverse effects , Heparin Antagonists , Humans , Protamines
4.
J Thromb Haemost ; 18(9): 2215-2219, 2020 09.
Article in English | MEDLINE | ID: mdl-32668058

ABSTRACT

BACKGROUND: Thirty percent of Covid-19 patients admitted to intensive care units present with thrombotic complications despite thromboprophylaxis. Bed rest, obesity, hypoxia, coagulopathy, and acute excessive inflammation are potential mechanisms reported by previous studies. Better understanding of the underlying mechanisms leading to thrombosis is crucial for developing more appropriate prophylaxis and treatment strategies. OBJECTIVE: We aimed to assess fibrinolytic activity and thrombin generation in 78 Covid-19 patients. PATIENTS AND METHODS: Forty-eight patients admitted to the intensive care unit and 30 patients admitted to the internal medicine department were included in the study. All patients received thromboprophylaxis. We measured fibrinolytic parameters (tissue plasminogen activator, PAI-1, thrombin activatable fibrinolysis inhibitor, alpha2 anti-plasmin, and tissue plasminogen activator-modified ROTEM device), thrombin generation, and other coagulation tests (D-dimer, fibrinogen, factor VIII, antithrombin). RESULTS AND CONCLUSIONS: We observed two key findings: a high thrombin generation capacity that remained within normal values despite heparin therapy and a hypofibrinolysis mainly associated with increased PAI-1 levels. A modified ROTEM is able to detect both hypercoagulability and hypofibrinolysis simultaneously in Covid-19 patients with thrombosis.


Subject(s)
COVID-19/blood , COVID-19/complications , Fibrinolysis , Thrombin/metabolism , Thrombosis/complications , Adult , Aged , Blood Coagulation , Blood Coagulation Factors/metabolism , Blood Coagulation Tests , COVID-19 Nucleic Acid Testing , Critical Care , Female , Humans , Inflammation , Intensive Care Units , Male , Middle Aged , Renal Replacement Therapy , Respiration, Artificial , Risk , Venous Thromboembolism/complications
SELECTION OF CITATIONS
SEARCH DETAIL
...